US20060270731A1 - Pure duloxetine hydrochloride - Google Patents

Pure duloxetine hydrochloride Download PDF

Info

Publication number
US20060270731A1
US20060270731A1 US11/376,754 US37675406A US2006270731A1 US 20060270731 A1 US20060270731 A1 US 20060270731A1 US 37675406 A US37675406 A US 37675406A US 2006270731 A1 US2006270731 A1 US 2006270731A1
Authority
US
United States
Prior art keywords
duloxetine
percent
enantiomer
iso3
dlx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/376,754
Inventor
Santiago Ini
Mili Abramov
Anita Liberman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals USA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/376,754 priority Critical patent/US20060270731A1/en
Assigned to TEVA PHARMACEUTICALS USA, INC. reassignment TEVA PHARMACEUTICALS USA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TEVA PHARMACEUTICAL INDUSTRIES LTD
Assigned to TEVA PHARMACEUTICAL INDUSTRIES LTD. reassignment TEVA PHARMACEUTICAL INDUSTRIES LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIBERMAN, ANITA, ABRAMOV, MILI, INI, SANTIAGO
Publication of US20060270731A1 publication Critical patent/US20060270731A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Abstract

Chemically and/or enantiomerically pure duloxetine HCl and process for preparing chemically and/or enantiomerically pure duloxetine HCl are provided.

Description

    RELATED APPLICATIONS
  • This application claims benefit of U.S. Provisional Application Nos. 60/726,502, filed Oct. 12, 2005, 60/736,746, filed Nov. 14, 2005, 60/661,711, filed Mar. 14, 2005, and 60/773,593, filed Feb. 14, 2006
    • FIELD OF THE INVENTION
  • The present invention relates to chemically and/or enantiomerically pure duloxetine hydrochloride.
    • BACKGROUND OF THE INVENTION
  • Duloxetine HCl is a dual reuptake inhibitor of the neurotransmitters serotonin and norepinephrine. It is used for the treatment of stress urinary incontinence (SUI), depression, and pain management. It is commercially available as CYMBALTA®. Duloxetine hydrochloride has the chemical name (S)-(+)-N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine hydrochloric acid salt and the following structure.
    Figure US20060270731A1-20061130-C00001
  • Duloxetine, as well as processes for its preparation, is disclosed in a few published documents, such as U.S. Pat. No. 5,023,269, EP Patent No. 457559, and U.S. Pat. No. 6,541,668.
  • The conversion of duloxetine to its hydrochloride salt is described in U.S. Pat. No. 5,491,243 and in Wheeler W. J., et al, J. Label. Cpds. Radiopharm, 1995, 36, 312. In both cases the reactions are performed in ethyl acetate.
  • Like any synthetic compound, duloxetine HCl can contain extraneous compounds or impurities that can come from many sources. They can be unreacted starting materials, by-products of the reaction, products of side reactions, or degradation products. Impurities in duloxetine HCl or any active pharmaceutical ingredient (API) are undesirable, and, in extreme cases, might even be harmful to a patient being treated with a dosage form of the API in which a sufficient amount of impurities is present. Furthermore, the undesired enantiomeric impurities reduce the level of the API available in the pharmaceutical composition.
  • It is also known in the art that impurities in an API may arise from degradation of the API itself, which is related to the stability of the pure API during storage, and the manufacturing process, including the chemical synthesis. Process impurities include unreacted starting materials, chemical derivatives of impurities contained in starting materials, synthetic by-products, and degradation products.
  • In addition to stability, which is a factor in the shelf life of the API, the purity of the API produced in the commercial manufacturing process is clearly a necessary condition for commercialization. Impurities introduced during commercial manufacturing processes must be limited to very small amounts, and are preferably substantially absent. For example, the ICH Q7A guidance for API manufacturers requires that process impurities be maintained below set limits by specifying the quality of raw materials, controlling process parameters, such as temperature, pressure, time, and stoichiometric ratios, and including purification steps, such as crystallization, distillation, and liquid-liquid extraction, in the manufacturing process.
  • The product mixture of a chemical reaction is rarely a single compound with sufficient purity to comply with pharmaceutical standards. Side products and by-products of the reaction and adjunct reagents used in the reaction will, in most cases, also be present in the product mixture. At certain stages during processing of an API, such as duloxetine hydrochloride, it must be analyzed for purity, typically, by HPLC or TLC analysis, to determine if it is suitable for continued processing and, ultimately, for use in a pharmaceutical product. The API need not be absolutely pure, as absolute purity is a theoretical ideal that is typically unattainable. Rather, purity standards are set with the intention of ensuring that an API is as free of impurities as possible, and, thus, is as safe as possible for clinical use. In the United States, the Food and Drug Administration guidelines recommend that the amounts of some impurities be limited to less than 0.1 percent.
  • Generally, side products, by-products, and adjunct reagents (collectively “impurities”) are identified spectroscopically and/or with another physical method, and then associated with a peak position, such as that in a chromatogram or a spot on a TLC plate. (Strobel p. 953, Strobel, H. A.; Heineman, W. R., Chemical Instrumentation: A Systematic Approach, 3rd dd. (Wiley & Sons: New York 1989)). Thereafter, the impurity can be identified, e.g., by its relative position in the chromatogram, where the position in a chromatogram is conventionally measured in minutes between injection of the sample on the column and elution of the particular component through the detector. The relative position in the chromatogram is known as the “retention time.”
  • The retention time can vary about a mean value based upon the condition of the instrumentation, as well as many other factors. To mitigate the effects such variations have upon accurate identification of an impurity, practitioners use the “relative retention time” (“RRT”) to identify impurities. (Strobel p. 922). The RRT of an impurity is its retention time divided by the retention time of a reference marker. It may be advantageous to select a compound other than the API that is added to, or present in, the mixture in an amount sufficiently large to be detectable and sufficiently low as not to saturate the column, and to use that compound as the reference marker for determination of the RRT.
  • (+)-N-methyl-3-(1-naphtalenyloxy)-3-(3-thienyl)propanamine is disclosed by Olsen B. A et al, as an impurity obtained in the preparation of duloxetine (J. Lib. Chrom. & Rel. Technol, 1996, 19, 1993).
  • There is a need in the art for duloxetine HCl, having improved chemical and/or enantiomeric purity, compared to duloxetine HCl obtained with prior art methods. The present invention provides such a duloxetine hydrochloride, having improved chemical and/or enantiomeric purity.
    • SUMMARY OF THE INVENTION
  • In one embodiment, the present invention encompasses pharmaceutically acceptable salts of duloxetine, containing less than about 0.14 percent area by HPLC of the impurity (+)-N-methyl-3-(1-naphtalenyloxy)-3-(3-thienyl)propanamine (DLX-ISO3).
  • In another embodiment, the present invention encompasses pharmaceutically acceptable salts of duloxetine, containing less than about 0.04 percent area by HPLC of the duloxetine R-enantiomer.
  • In another embodiment, the present invention encompasses pharmaceutically acceptable salts of duloxetine, containing less than about 0.14 percent area by HPLC of the impurity DLX-ISO3 and less than about 0.04 percent area by HPLC of the duloxetine R-enantiomer.
  • In another embodiment, the present invention encompasses duloxetine hydrochloride (HCl), containing less than about 0.14 percent area by HPLC of the impurity DLX-ISO3.
  • In another embodiment, the present invention encompasses duloxetine HCl, containing less than about 0.04 percent area by HPLC of the duloxetine R-enantiomer.
  • In another embodiment, the present invention encompasses duloxetine HCl, containing less than about 0.14 percent area by HPLC of the impurity DLX-ISO3 and less than about 0.04 percent area by HPLC of the duloxetine R-enantiomer.
  • In another embodiment, the present invention encompasses pharmaceutical formulations comprising the chemically and/or enantiomerically pure duloxetine HCl or any other pharmaceutically acceptable salts of duloxetine, described above.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIGS. 1 and 2 depict HPLC chromatograms of the commercial tablet CYMBALTA®, showing a RRT of 1.20 for DLX-ISO3 and a RRT of 1.50 for the duloxetine R-enantiomer, respectively.
    • DETAILED DESCRIPTION OF THE INVENTION
  • As used herein the term “crystallization” refers to a process comprising heating a mixture of a starting material and a solvent to a temperature of between about 110° C. below and above the reflux temperature of the solvent to obtain a solution, and cooling the solution to a temperature of about 0° C. to about 30° C.
  • The present invention provides chemically and/or enantiomerically pure pharmaceutically acceptable salts of duloxetine
  • The present invention also provides chemically and/or enantiomerically pure duloxetine hydrochloride.
  • The chemical purity of duloxetine in the present invention relates to the level of the impurity (+)-N-methyl-3-(1-naphtalenyloxy)-3-(3-thienyl) propanamine, referred to herein as DLX-ISO3, and represented by the formula:
    Figure US20060270731A1-20061130-C00002
  • The enantiomeric purity in the present invention relates to the level of the R-enantiomer of duloxetine, (R)-(−)-N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine, represented by the formula:
    Figure US20060270731A1-20061130-C00003
  • As used herein, the terms “chemically pure duloxetine HCl” and “chemically pure pharmaceutically acceptable salt of duloxetine” refer to duloxetine hydrochloride/pharmaceutically acceptable salt of duloxetine, containing less than about 0.14 percent area by HPLC of the DLX-ISO3 impurity. Preferably, the level of DLX-ISO3 is less than about 0.07 percent area by HPLC, and, most preferably, is less than about 0.02 percent area by HPLC. A chemically pure duloxetine HCl/pharmaceutically acceptable salt of duloxetine in accordance with the invention may be substantially free of DLX-ISO3, such that the DLX-ISO3 is below the detection limit; i.e., the chemically pure duloxetine HCl/pharmaceutically acceptable salt of duloxetine preferably contains essentially 0.0 percent DLX-ISO3 within the error limits of the detection.
  • As used herein, the term “enantiomerically pure duloxetine HCl” and “enantiomerically pure pharmaceutically acceptable salt of duloxetine” refer to a duloxetine HCl/pharmaceutically acceptable salt of duloxetine, containing less than about 0.04 percent area by HPLC of the duloxetine R-enantiomer. Preferably, the level of the duloxetine R-enantiomer is less than about 0.03 percent area by HPLC, and, more preferably, is less than about 0.02 percent area by HPLC. An enantiomerically pure duloxetine HCl/pharmaceutically acceptable salt of duloxetine in accordance with the invention may be substantially free of the R-enantiomer, such that the R-enantiomer is below the detection limit; i.e., the enantiomerically pure duloxetine HCl/pharmaceutically acceptable salt of duloxetine preferably contains essentially 0.0 percent R-enantiomer within the error limits of the detection.
  • The present invention also provides a process for the preparation of the duloxetine HCl described above. This process comprises dissolving duloxetine in water or a solvent selected from the group consisting of acetone, methyl ethyl ketone (MEK), methyl t-butyl ether (MTBE), ethanol, isopropanol, and n-butanol, and mixtures thereof with water, and crystallizing duloxetine HCl. Preferably, the solvent is a mixture of acetone and water or isopropanol.
  • Preferably, when the solvent is in a mixture with water, the ratio (vol/vol) of the solvent and water is at least about 97:3 to about 98.25:1.75, and, more preferably, the ratio is at least about 98:2. Preferably, the ratio (vol/vol) of the starting material and the water or solvent is about 1:10. Preferably, the dissolution occurs at reflux temperature. Preferably, after cooling, the solution is maintained while stirring, for about 10 minutes to about 24 hours.
  • Preferably, the duloxetine HCl obtained after the crystallization contains less than about 0.14 percent area by HPLC DLX-ISO3 and less than about 0.04 percent of the R-enantiomer of duloxetine. The crystallization process may be repeated in order to increase the chemical and enantiomeric purity even further either with the same or a different solvent that was used for the first crystallization.
  • The present invention further provides pharmaceutical formulations comprising the duloxetine HCl or any other pharmaceutically acceptable salts of duloxetine, described above.
  • Pharmaceutical compositions may be prepared as medicaments to be administered orally, parenterally, rectally, transdermally, bucally, or nasally. Suitable forms for oral administration include tablets, compressed or coated pills, dragees, sachets, hard or gelatin capsules, sub-lingual tablets, syrups, and suspensions. Suitable forms of parenteral administration include an aqueous or non-aqueous solution or emulsion, while for rectal administration, suitable forms for administration include suppositories with hydrophilic or hydrophobic vehicle. For topical administration, the invention provides suitable transdermal delivery systems known in the art, and for nasal delivery, there are provided suitable aerosol delivery systems known in the art.
  • In addition to the active ingredient(s), the pharmaceutical compositions of the present invention may contain one or more excipients or adjuvants. Selection of excipients and the amounts to use may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
  • Diluents increase the bulk of a solid pharmaceutical composition, and may make a pharmaceutical dosage form containing the composition easier for the patient and care giver to handle. Diluents for solid compositions include, for example, microcrystalline cellulose (e.g., AVICEL®), microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g., EUDRAGIT®), potassium chloride, powdered cellulose, sodium chloride, sorbitol, and talc.
  • Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet, may include excipients whose functions include helping to bind the active ingredient and other excipients together after compression. Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g., carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g., KLUCEL®), hydroxypropyl methyl cellulose (e.g., METHOCEL®), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g., KOLLIDON®, PLASDONE®), pregelatinized starch, sodium alginate, and starch.
  • The dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach may be increased by the addition of a disintegrant to the composition. Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g., AC-DI-SOL®, PRIMELLOSE®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g., KOLLIDON®, POLYPLASDONE®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g., Explotab®), and starch.
  • Glidants can be added to improve the flowability of a non-compacted solid composition and to improve the accuracy of dosing. Excipients that may function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, and tribasic calcium phosphate.
  • When a dosage form such as a tablet is made by the compaction of a powdered composition, the composition is subjected to pressure from a punch and die. Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and die, which can cause the product to have pitting and other surface irregularities. A lubricant can be added to the composition to reduce adhesion and ease the release of the product from the die. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate.
  • Flavoring agents and flavor enhancers make the dosage form more palatable to the patient. Common flavoring agents and flavor enhancers for pharmaceutical products that may be included in the composition of the present invention include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.
  • Solid and liquid compositions may also be died using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.
  • In liquid pharmaceutical compositions of the present invention, the active ingredient and any other solid excipients are suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin.
  • Liquid pharmaceutical compositions may contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier. Emulsifying agents that may be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, and cetyl alcohol.
  • Liquid pharmaceutical compositions of the present invention may also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract. Such agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, and xanthan gum.
  • Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol, and invert sugar may be added to improve the taste.
  • Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole, and ethylenediamine tetraacetic acid may be added at levels safe for ingestion to improve storage stability.
  • According to the present invention, a liquid composition may also contain a buffer such as gluconic acid, lactic acid, citric acid or acetic acid, sodium gluconate, sodium lactate, sodium citrate, or sodium acetate.
  • Selection of excipients and the amounts used may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
  • The solid compositions of the present invention include powders, granulates, aggregates, and compacted compositions. The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant, and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral. The dosages may be conveniently presented in unit dosage form and prepared by any of the methods well known in the pharmaceutical arts.
  • Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches, and lozenges, as well as liquid syrups, suspensions, and elixirs.
  • The dosage form of the present invention may be a capsule, containing the composition, preferably a powdered or granulated solid composition of the invention, within either a hard or soft shell. The shell may be made from gelatin, and, optionally, contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.
  • The active ingredient and excipients may be formulated into compositions and dosage forms according to methods known in the art.
  • A composition for tableting or capsule filling may be prepared by wet granulation. In wet granulation, some or all of the active ingredients and excipients in powder form are blended, and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules. The granulate is screened and/or milled, dried, and then screened and/or milled to the desired particle size. The granulate may then be tableted or other excipients may be added prior to tableting, such as a glidant and/or a lubricant.
  • A tableting composition may be prepared conventionally by dry blending. For example, the blended composition of the actives and excipients may be compacted into a slug or a sheet, and then comminuted into compacted granules. The compacted granules may subsequently be compressed into a tablet.
  • As an alternative to dry granulation, a blended composition may be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules. Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate, and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.
  • A capsule filling of the present invention may comprise any of the aforementioned blends and granulates that were described with reference to tableting, however, they are not subjected to a final tableting step.
  • Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following examples, describing in detail the analysis of the duloxetine HCl and methods for preparing the duloxetine HCl of the invention.
  • It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
    • EXAMPLES
  • HPLC Method for Measuring Chemical Purity:
  • Column: Hypersyl Gold (150×4.6 5μ)
  • Mobile phase:
      • (A) 63% (KH2PO4 (0.02M) pH-2.5): 37% (35% MeOH: 10% THF)
      • (B) 20% (KH2PO4 (0.02M) pH-2.5): 80% ACN
        Gradient:
      • From 0 to 15 min (A) isocraticaly
      • From 15 to 60 min (B) increases from 0 to 100%
        Detection: 230 nm
        Flow: 1 mL/min
        Detection limit: 0.02%
        HPLC Method for Measuring Enantiomeric Purity:
        Column: Diacel Chiral OD 250×4.6 5μ
        Eluent: Hexane (900 mL): IPA (100 mL): DEA (2 mL)
        Flow: 1 mL/min
        Detection: 230 nm
        Sample conc: 0.5 mg/mL
        Sample vol: 100 μL
        Column temp: 20° C.
        Detection limit: 0.02%
    Example 1 Purification of Duloxetine Hydrochloride in Acetone/Water Example 1a
  • A mixture of 20 g Duloxetine hydrochloride in 204 ml acetone/water (98:2) was heated to reflux. After the compound was dissolved, the oil bath was removed, and the solution was cooled to 15° C. overnight. The solid was filtered, washed with acetone, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (78 percent yield), containing DLX-ISO3 (0.21 percent) and enantiomer R (<0.03 percent)
    • Example 1b
  • A mixture of 13 g of the previously obtained Duloxetine hydrochloride in 130 ml acetone/water (98:1.5) was heated to reflux. After the compound was dissolved, the oil bath was removed, and the solution was cooled to 110° C. for 2 hours. The solid was filtered, washed with acetone, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (87 percent yield), containing DLX-ISO3 (0.15 percent) and free of enantiomer R.
    • Example 1c
  • A mixture of 10 g of the previously obtained Duloxetine hydrochloride in 100 ml acetone/water (98:2) was heated to reflux. After the compound was dissolved, the oil bath was removed, and the solution was cooled to room temperature and stirred for 1 hour. The solid was filtered, washed with acetone, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (80 percent yield), containing DLX-ISO3 (0.07 percent), and free of enantiomer R.
    • Example 1d
  • A mixture of 7.5 g of the previously obtained Duloxetine hydrochloride in 75 ml acetone/water (98:2) was heated to reflux. After the compound was dissolved, the oil bath was removed, and the solution was cooled to room temperature, and stirred for 2 hours. The solid was filtered, washed with acetone, and dried in a vacuum oven at 40° C. for 16 hours, giving Duloxetine hydrochloride (73 percent yield), containing DLX-ISO3 (0.03 percent), and free of enantiomer R.
    • Example 2 Purification of Duloxetine Hydrochloride in Acetone/Water Under Different Conditions Example 2a
  • A mixture of 16 g Duloxetine hydrochloride (contaminated with 0.30 percent DLX-ISO3 and 0.13 percent enantiomer R) in 160 ml acetone was heated to reflux, and then 4 ml of water were added till complete dissolution. After the compound was dissolved, the oil bath was removed, and the solution was cooled to room temperature and stirred for one hour. The solid was filtered, washed with acetone, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (68 percent yield), containing DLX-ISO3 (0.10 percent) and free of enantiomer R.
    • Example 2b
  • A mixture of 8 g of the previously obtained Duloxetine hydrochloride in 80 ml acetone was heated to reflux, and 2 ml of water were added. After the compound was dissolved, the oil bath was removed, and the solution was cooled to room temperature and stirred for half hour. The solid was filtered, washed with acetone, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (36 percent yield), containing DLX-ISO3 (0.06 percent).
    • Example 2c
  • A mixture of 2 g of the previously obtained Duloxetine hydrochloride in 20 ml of acetone was heated to reflux, and 0.4 ml of water were added. After the compound was dissolved, the oil bath was removed, and the solution was cooled to room temperature and stirred for three hours. The solid was filtered, washed with acetone, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (50 percent yield) free of DLX-ISO3.
    • Example 3 Purification of Duloxetine Hydrochloride in Ethyl Acetate
  • A mixture of 2 g Duloxetine hydrochloride (contaminated with 0.46 percent DLX-ISO3 and 0.13 percent enantiomer R) in 10 ml ethyl acetate was heated to reflux, and 50 ml of ethyl acetate were added. The mixture was stirred at the same temperature for 40 minutes, followed by cooling to room temperature and stirring for two hours. The solid was filtered, washed with ethyl acetate, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (93 percent yield), containing DLX-ISO3 (0.28 percent) and 0.07 percent of enantiomer R.
  • Example 3 was repeated to yield Duloxetine hydrochloride, containing less than 0.14 percent DLX-ISO3.
    • Example 4 Purification of Duloxetine Hydrochloride in IPA Example 4a
  • A mixture of 8.4 g Duloxetine hydrochloride (contaminated with 0.29 percent DLX-ISO3 and 0.17 percent enantiomer R) in 84 ml IPA was heated to reflux. The solution was stirred at the same temperature for 15 minutes, followed by cooling to room temperature and stirring for two hours. The solid was filtered, washed with IPA, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (62 percent yield), containing DLX-ISO3 (0.21 percent) and free of enantiomer R.
    • Example 4b
  • A mixture of 8.8 g Duloxetine hydrochloride (contaminated with 0.21 percent DLX-ISO3) in 70 ml IPA was heated to reflux. The solution was stirred at the same temperature for 15 minutes, followed by cooling to room temperature and stirring for two hours. The solid was filtered, washed with IPA, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (83 percent yield), containing DLX-ISO3 (0.17 percent).
    • Example 4c
  • A mixture of 5 g Duloxetine hydrochloride (contaminated with 0.17 percent DLX-ISO3) in 40 ml IPA was heated to reflux. The solution was stirred at the same temperature for 15 minutes, followed by cooling to room temperature and stirring for two hours. The solid was filtered, washed with IPA, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (65 percent yield), containing DLX-ISO3 (0.13 percent)
    • Example 5 Purification of Duloxetine Hydrochloride in MTBE/Water Example 5a
  • A mixture of 12 g Duloxetine hydrochloride (contaminated with 0.29 percent DLX-ISO3 and 0.11 percent enantiomer) in 120 ml MTBE was heated to reflux, and 3.6 ml of water were added until complete dissolution. The two phase solution was stirred at the same temperature for 15-30 minutes, followed by cooling to room temperature and stirring overnight. The solid was filtered, washed with the same solvents, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (29 percent yield), containing DLX-ISO3 (0.16 percent) and less than 0.02 percent of enantiomer R.
    • Example 5b
  • A mixture of 2 g Duloxetine hydrochloride (contaminated with 0.16 percent DLX-ISO3 and less than 0.03 percent of enantiomer R) in 20 ml MTBE is heated to reflux, and 0.36 ml of water are added until complete dissolution. The two phase solution is stirred at the same temperature for 15 to 30 minutes, followed by cooling to room temperature and stirring overnight. The solid is filtered, washed with the same solvents, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (29 percent yield).
    • Example 6 Purification of Duloxetine Hydrochloride in MEK/Water Example 6a
  • A mixture of 4 g Duloxetine hydrochloride (contaminated with 0.30 percent DLX-ISO3 and 0.17 percent enantiomer R) in 20 ml MEK was heated to reflux, and 0.6 ml of water were added until complete dissolution. The solution was stirred at the same temperature for 15-30 minutes, followed by cooling to 0° to 5° C. and stirring for two hours. The solid was filtered, washed with the same solvents, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (32 percent yield), containing DLX-ISO3 (0.10 percent) and free of enantiomer R.
    • Example 6b
  • A mixture of 0.5 g Duloxetine hydrochloride (contaminated with 0.10 percent DLX-ISO3) in 2.5 ml MEK is heated to reflux, and 0.1 ml of water are added until complete dissolution. The solution is stirred at the same temperature for 15 to 30 minutes, followed by cooling to 0° to 5° C. and stirring for two hours. The solid is filtered, washed with the same solvents, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (32 percent yield).
    • Example 7 Purification of Duloxetine Hydrochloride in Water
  • A mixture of 2.7 g Duloxetine hydrochloride (contaminated with 0.50 percent DLX-ISO3 and 0.29 percent enantiomer R) in 27 ml water was heated to reflux. The solution was stirred at the same temperature for 10 to 15 minutes, followed by cooling to room temperature and stirring overnight. The solid was filtered, washed with water, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (61 percent yield), containing DLX-ISO3 (0.25 percent) and free of enantiomer R.
  • Example 7 is repeated to yield Duloxetine hydrochloride, containing less than 0.14 percent DLX-ISO3.
    • Example 8 Purification of Duloxetine Hydrochloride in MEK
  • A mixture of 2 g Duloxetine hydrochloride (contaminated with 0.26 percent DLX-ISO3 and 0.17 percent enantiomer R) in 40 ml MEK was heated to reflux. The solution was stirred at the same temperature for 30 minutes, followed by cooling to 0° to 5° C. and stirring for 2 hours. The solid was filtered, washed with MEK, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (60 percent yield) contaminated with DLX-ISO3 (0.21 percent) and free of enantiomer R.
  • Example 8 is repeated to yield Duloxetine hydrochloride, containing less than 0.14 percent DLX-ISO3.
    • Example 9 Purification of Duloxetine Hydrochloride in Acetone Example 9a
  • A mixture of 2 g Duloxetine hydrochloride (contaminated with 0.46 percent DLX-ISO3 and 0.13 percent enantiomer R) in 130 ml acetone was heated to reflux. The solution was stirred at the same temperature for one hour, followed by cooling to 27° C. The solid was filtered at the same temperature, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (59.50 percent yield), containing DLX-ISO3 (0.17 percent) and free of enantiomer R.
    • Example 9b
  • A mixture of 1 g Duloxetine hydrochloride (contaminated with 0.17 percent DLX-ISO3) in 65 ml acetone was heated to reflux. The solution was stirred at the same temperature for one hour, followed by cooling to 27° C. The solid was filtered at the same temperature, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (59.50 percent yield).
    • Example 10 Purification of Duloxetine Hydrochloride in n-Butanol
  • A mixture of 2 g Duloxetine hydrochloride (contaminated with 0.26 percent DLX-ISO3 and 0.17 percent enantiomer R) in 12 ml n-butanol was heated to reflux. The solution was stirred at the same temperature for 10 minutes, followed by cooling to room temperature and stirring for 1 hour. The solid was filtered, washed with n-butanol, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (75 percent yield), containing DLX-ISO3 (0.24 percent) and 0.07 percent of enantiomer R.
  • Example 10 is repeated, using a solvent selected from: C2-5 ketones, C2-5 alkyl esters, C2-5 alkyl ethers, C2-4 alkanols other than n-butanol and mixtures thereof with water to yield Duloxetine hydrochloride, containing less than 0.14 percent DLX-ISO3.
    • Example 11 Purification of Duloxetine Hydrochloride in Ethanol
  • A mixture of 2.22 g Duloxetine hydrochloride (contaminated with 0.28 percent DLX-ISO3 and 0.50 percent enantiomer R) in 22.2 ml ethanol was heated to reflux. The solution was stirred at the same temperature for 15 minutes, followed by cooling to room temperature and stirring for 1 hour. The solid was filtered, washed with n-butanol, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (36 percent yield), containing DLX-ISO3 (0.21 percent) and free of enantiomer R.
  • Example 11 is repeated to yield Duloxetine hydrochloride, containing less than 0.14 percent DLX-ISO3.
    • Example 12 Analysis of CYMBALTA® Tablets
  • CYMBALTA® tablets were analyzed, and found to contain 0.16 percent of the impurity (+)-N-methyl-3-(1-naphtalenyloxy)-3-(3-thienyl)propanamine. The tablet also contained 0.04 percent of the undesired R-enantiomer. HPLC chromatograms of a CYMBALTA® tablet are depicted in FIGS. 1 and 2, showing a RRT of 1.20 for DLX-ISO3 and a RRT of 1.50 for the duloxetine R-enantiomer, respectively.
    • COMPARATIVE EXAMPLE
  • The procedure disclosed in U.S. Pat. No. 5,491,243 was repeated as follows: to a solution of 7 g Duloxetine base in 21 ml ethyl acetate were added 0.8 ml. of concentrated HCl and stirred at room temperature. After an hour the solution was cooled to 0-5° C. and stirred for an additional two hours. The resulting solid was filtered, washed with the same solvent, and dried in a vacuum oven at 45° C. for 16 hours. Duloxetine hydrochloride was obtained in 42 percent yield, containing DLX-ISO3 (0.30 percent) and 0.35 percent of enantiomer R.
  • While it is apparent that the invention disclosed herein is well calculated to fulfill the objects stated above, it will be appreciated that numerous modifications and embodiments may be devised by those skilled in the art. Therefore, it is intended that the appended claims cover all such modifications and embodiments as falling within the true spirit and scope of the present invention.

Claims (26)

1. Pharmaceutically acceptable salts of duloxetine, containing less than about 0.14 percent area by HPLC of the impurity (+)-N-methyl-3-(1-naphtalenyloxy)-3-(3-thienyl)propanamine (DLX-ISO3).
2. The pharmaceutically acceptable salts of claim 1, containing less than about 0.07 percent area by HPLC of DLX-ISO3.
3. The pharmaceutically acceptable salts of claim 2, containing less than about 0.02 percent area by HPLC of DLX-ISO3.
4. The pharmaceutically acceptable salts of claim 3, containing about 0.0 percent area by HPLC of DLX-ISO3.
5. Pharmaceutically acceptable salts of duloxetine, containing less than about 0.04 percent area by HPLC of the duloxetine R-enantiomer.
6. The pharmaceutically acceptable salts of claim 5, containing less than about 0.03 percent area by HPLC of the duloxetine R-enantiomer.
7. The pharmaceutically acceptable salts of claim 6, containing less than about 0.02 percent area by HPLC of the duloxetine R-enantiomer.
8. The pharmaceutically acceptable salts of claim 7, containing about 0.0 percent area by HPLC of the duloxetine R-enantiomer.
9. The pharmaceutically acceptable salts of any of claims 1 to 4, containing less than about 0.04 percent area by HPLC of the duloxetine R-enantiomer.
10. The pharmaceutically acceptable salts of claim 9, containing less than about 0.03 percent area by HPLC of the duloxetine R-enantiomer.
11. The pharmaceutically acceptable salts of claim 10, containing less than about 0.02 percent area by HPLC of the duloxetine R-enantiomer.
12. The pharmaceutically acceptable salts of claim 11, containing about 0.0 percent area by HPLC of the duloxetine R-enantiomer.
13. Duloxetine hydrochloride (HCl), containing less than about 0.14 percent area by HPLC of the impurity (+)-N-methyl-3-(1-naphtalenyloxy)-3-(3-thienyl)propanamine (DLX-ISO3).
14. The duloxetine HCl of claim 13, containing less than about 0.07 percent area by HPLC of DLX-ISO3.
15. The duloxetine HCl of claim 14, containing less than about 0.02 percent area by HPLC of DLX-ISO3.
16. The duloxetine HCl of claim 15, containing about 0.0 percent area by HPLC of DLX-ISO3.
17. Duloxetine HCl, containing less than about 0.04 percent area by HPLC of the duloxetine R-enantiomer.
18. The duloxetine HCl of claim 17, containing less than about 0.03 percent area by HPLC of the duloxetine R-enantiomer.
19. The duloxetine HCl of claim 18, containing less than about 0.02 percent area by HPLC of the duloxetine R-enantiomer.
20. The duloxetine HCl of claim 19, containing about 0.0 percent area by HPLC of the duloxetine R-enantiomer.
21. The duloxetine HCl of any of claims 13 to 16, containing less than about 0.04 percent area by HPLC of the duloxetine R-enantiomer.
22. The duloxetine HCl of claim 21, containing less than about 0.03 percent area by HPLC of the duloxetine R-enantiomer.
23. The duloxetine HCl of claim 22, containing less than about 0.02 percent area by HPLC of the duloxetine R-enantiomer.
24. The duloxetine HCl of claim 23, containing about 0.0 percent area by HPLC of the duloxetine R-enantiomer.
25. A pharmaceutical formulation, comprising the pharmaceutically acceptable salts of any of claims 1 to 12.
26. A pharmaceutical formulation, comprising the duloxetine HCl of any of claims 13 to 24.
US11/376,754 2005-03-14 2006-03-14 Pure duloxetine hydrochloride Abandoned US20060270731A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/376,754 US20060270731A1 (en) 2005-03-14 2006-03-14 Pure duloxetine hydrochloride

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66171105P 2005-03-14 2005-03-14
US72650205P 2005-10-12 2005-10-12
US73674605P 2005-11-14 2005-11-14
US77359306P 2006-02-14 2006-02-14
US11/376,754 US20060270731A1 (en) 2005-03-14 2006-03-14 Pure duloxetine hydrochloride

Publications (1)

Publication Number Publication Date
US20060270731A1 true US20060270731A1 (en) 2006-11-30

Family

ID=36593962

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/376,552 Expired - Fee Related US7534900B2 (en) 2005-03-14 2006-03-14 Process for the purification of duloxetine hydrochloride
US11/376,574 Abandoned US20060258871A1 (en) 2005-03-14 2006-03-14 (S)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof
US11/376,573 Abandoned US20060270861A1 (en) 2005-03-14 2006-03-14 Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine
US11/376,754 Abandoned US20060270731A1 (en) 2005-03-14 2006-03-14 Pure duloxetine hydrochloride

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US11/376,552 Expired - Fee Related US7534900B2 (en) 2005-03-14 2006-03-14 Process for the purification of duloxetine hydrochloride
US11/376,574 Abandoned US20060258871A1 (en) 2005-03-14 2006-03-14 (S)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof
US11/376,573 Abandoned US20060270861A1 (en) 2005-03-14 2006-03-14 Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine

Country Status (7)

Country Link
US (4) US7534900B2 (en)
EP (4) EP1858874A1 (en)
CA (2) CA2599478A1 (en)
IL (3) IL184184A0 (en)
MX (2) MX2007011255A (en)
TW (2) TW200639162A (en)
WO (4) WO2006099459A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194869A1 (en) * 2004-12-23 2006-08-31 Santiago Ini Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
US20060276660A1 (en) * 2005-03-14 2006-12-07 Santiago Ini Process for the purification of duloxetine hydrochloride
US20070281989A1 (en) * 2006-05-31 2007-12-06 Santiago Ini Process for preparing duloxetine and intermediates thereof
US20080027128A1 (en) * 2006-05-23 2008-01-31 Santiago Ini Duloxetine HCL polymorphs
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
US20090012316A1 (en) * 2005-03-08 2009-01-08 Teva Pharmaceuticals Usa, Inc. Crystal forms of (S)-(+)-N,N-dimethyl-3-(1-Napathalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof
WO2011148380A1 (en) * 2010-05-25 2011-12-01 Hetero Research Foundation Oral pharmaceutical composition of duloxetine

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838692A2 (en) 2005-09-22 2007-10-03 Teva Pharmaceutical Industries Ltd Dnt-maleate and methods of preparation thereof
EP1863782A1 (en) 2005-12-05 2007-12-12 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphtol) thiophene, an imputity of duloxetine hydrochloride
ATE507215T1 (en) 2005-12-12 2011-05-15 Medichem Sa IMPROVED SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS
CZ299270B6 (en) * 2006-01-04 2008-06-04 Zentiva, A. S. Process for preparing (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride
US8362279B2 (en) 2006-01-06 2013-01-29 Msn Laboratories Limited Process for pure duloxetine hydrochloride
GB0612508D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
GB0612509D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
CZ300116B6 (en) * 2006-12-05 2009-02-11 Zentiva, A. S. Purification process of (S)-N-methyl-3-(1-naphtyloxy)-3-(2-thienyl) propylamine hydrochloride
US8269023B2 (en) * 2007-03-05 2012-09-18 Lupin Ltd. Process for preparation of duloxetine hydrochloride
WO2009109992A1 (en) * 2008-01-23 2009-09-11 Arch Pharmalabs Limited Novel process for preparation of duloxetine and intermediates for use therein
EP2107057A1 (en) * 2008-04-04 2009-10-07 Ranbaxy Laboratories Limited Process for the preparation of pure duloxetine hydrochloride
WO2009150238A2 (en) * 2008-06-13 2009-12-17 Krka, D.D. Novo Mesto Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives
ES2434250T3 (en) 2008-07-24 2013-12-16 Theravance, Inc. Compounds of 3- (phenoxyphenylmethyl) pyrrolidine
CZ304602B6 (en) * 2009-09-02 2014-07-30 Zentiva, K. S. Crystallization process of (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine hydrochloride)
CN103626735A (en) * 2012-08-28 2014-03-12 石药集团中奇制药技术（石家庄）有限公司 Duloxetine hydrochloride crystal form and preparation method thereof
CN104478849A (en) * 2014-02-14 2015-04-01 广东东阳光药业有限公司 Method for preparing noradrenaline reuptake dual inhibitor
JP2016172704A (en) * 2015-03-17 2016-09-29 株式会社トクヤマ Manufacturing method of duloxetine hydrochloride and duloxetine hydrochloride with novel crystal structure
JP2016222628A (en) * 2015-06-03 2016-12-28 株式会社トクヤマ Method for producing duloxetine hydrochloride

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105564A (en) * 1960-10-13 1963-10-01 Alfred N Ormond Apparatus for measuring static loads
US3433804A (en) * 1965-03-22 1969-03-18 Chemie Linz Ag Basic-substituted dithienylmethyl- and thienylphenylmethyl ethers and a process of making same
US3468759A (en) * 1957-02-28 1969-09-23 Spofa Spojene Farmaceuticke Z 6-azauracil riboside
US3814750A (en) * 1971-07-14 1974-06-04 Pfizer Basic ethers of 1-phenyl-2-(2-thienyl)ethanols
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4330546A (en) * 1979-09-14 1982-05-18 John Wyeth & Brother Limited 3-Aryl-3-aryloxypropylamines
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US5371240A (en) * 1992-11-30 1994-12-06 Torcan Chemical Ltd. Process for the preparation of pure thiophene derivatives
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
US6333198B1 (en) * 1998-06-10 2001-12-25 Glaxo Wellcome, Inc. Compound and its use
US6541668B1 (en) * 1999-04-09 2003-04-01 Eli Lilly And Company Methods for preparing 3-arloxy-3-arylpropylamines and intermediates thereof
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040249170A1 (en) * 2002-01-24 2004-12-09 Alfio Borghese Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine
US20050032782A1 (en) * 2003-05-23 2005-02-10 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
US20050250838A1 (en) * 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
US20060194869A1 (en) * 2004-12-23 2006-08-31 Santiago Ini Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
US20060205956A1 (en) * 2002-12-19 2006-09-14 Cipla Limited Process for preparing duloxetine and intermediates for use therein
US20060270861A1 (en) * 2005-03-14 2006-11-30 Santiago Ini Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022031A (en) * 1962-05-11 1966-03-09 Egyt Gyogyszervegyeszeti Gyar Improvements in or relating to basic esters of 3,5-dimethoxy-4-alkoxy-benzoic acids
KR880007433A (en) 1986-12-22 1988-08-27 메리 앤 터커 3-aryloxy-3-substituted propanamine
IL98108A0 (en) 1990-05-17 1992-06-21 Lilly Co Eli Chiral synthesis of 1-aryl-3-aminopropan-1-ols
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
DE10207586A1 (en) * 2002-02-22 2003-09-11 Degussa Production of N-methyl-3-hydroxy-3- (2-thienyl) propanamine via new thiophene derivatives containing carbamate groups as intermediates
US20060167278A1 (en) 2002-05-20 2006-07-27 Mitsubishi Rayon Co. Ltd. Propanolamine derivatives, process for preparation of 3-n-methylamino-1-(2-thienyl)-1-propanols and process for preparation of propanolamine derivatives
CA2493490A1 (en) * 2002-07-24 2004-01-29 Cypress Bioscience, Inc. Treatment of depression secondary to pain (dsp)
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
WO2005019199A1 (en) 2003-08-25 2005-03-03 Hetero Drugs Limited Amorphous duloxetine hydrochloride
GB0410470D0 (en) 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
US7550605B2 (en) * 2004-08-05 2009-06-23 Sun Pharmaceutical Industries Ltd. Process for preparation of an anitdepressant compound
CZ297560B6 (en) * 2004-10-26 2007-02-07 Zentiva, A. S. Process for preparing (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine)
US20060270859A1 (en) 2005-01-27 2006-11-30 Santiago Ini Duloxetine HCl polymorphs
AT501846B1 (en) 2005-02-16 2007-08-15 Fronius Int Gmbh DEVICE AND METHOD FOR IMPLEMENTING SOFTWARE UPDATES IN INVERTERS AND INVERTERS DESIGNED FOR SOFTWARE UPDATES
WO2006126213A1 (en) 2005-05-24 2006-11-30 Matrix Laboratories Ltd An improved process for the preparation of duloxetine
ATE507215T1 (en) 2005-12-12 2011-05-15 Medichem Sa IMPROVED SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS
US8362279B2 (en) 2006-01-06 2013-01-29 Msn Laboratories Limited Process for pure duloxetine hydrochloride
US7538232B2 (en) 2006-01-19 2009-05-26 Eli Lilly And Company Process for the asymmetric synthesis of duloxetine

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3468759A (en) * 1957-02-28 1969-09-23 Spofa Spojene Farmaceuticke Z 6-azauracil riboside
US3105564A (en) * 1960-10-13 1963-10-01 Alfred N Ormond Apparatus for measuring static loads
US3433804A (en) * 1965-03-22 1969-03-18 Chemie Linz Ag Basic-substituted dithienylmethyl- and thienylphenylmethyl ethers and a process of making same
US3814750A (en) * 1971-07-14 1974-06-04 Pfizer Basic ethers of 1-phenyl-2-(2-thienyl)ethanols
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4330546A (en) * 1979-09-14 1982-05-18 John Wyeth & Brother Limited 3-Aryl-3-aryloxypropylamines
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5023269A (en) * 1986-12-22 1991-06-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5371240A (en) * 1992-11-30 1994-12-06 Torcan Chemical Ltd. Process for the preparation of pure thiophene derivatives
US5491243A (en) * 1993-10-12 1996-02-13 Eli Lilly And Company Intermediate useful for the asymmetric synthesis of duloxetine
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
US6333198B1 (en) * 1998-06-10 2001-12-25 Glaxo Wellcome, Inc. Compound and its use
US6541668B1 (en) * 1999-04-09 2003-04-01 Eli Lilly And Company Methods for preparing 3-arloxy-3-arylpropylamines and intermediates thereof
US20040249170A1 (en) * 2002-01-24 2004-12-09 Alfio Borghese Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20060205956A1 (en) * 2002-12-19 2006-09-14 Cipla Limited Process for preparing duloxetine and intermediates for use therein
US20050032782A1 (en) * 2003-05-23 2005-02-10 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
US20050250838A1 (en) * 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
US20060194869A1 (en) * 2004-12-23 2006-08-31 Santiago Ini Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
US20060270861A1 (en) * 2005-03-14 2006-11-30 Santiago Ini Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine
US20060276660A1 (en) * 2005-03-14 2006-12-07 Santiago Ini Process for the purification of duloxetine hydrochloride

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194869A1 (en) * 2004-12-23 2006-08-31 Santiago Ini Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
US20090012316A1 (en) * 2005-03-08 2009-01-08 Teva Pharmaceuticals Usa, Inc. Crystal forms of (S)-(+)-N,N-dimethyl-3-(1-Napathalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof
US20060276660A1 (en) * 2005-03-14 2006-12-07 Santiago Ini Process for the purification of duloxetine hydrochloride
US7534900B2 (en) 2005-03-14 2009-05-19 Teva Pharmaceutical Industries Ltd Process for the purification of duloxetine hydrochloride
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
US20080027128A1 (en) * 2006-05-23 2008-01-31 Santiago Ini Duloxetine HCL polymorphs
US20070281989A1 (en) * 2006-05-31 2007-12-06 Santiago Ini Process for preparing duloxetine and intermediates thereof
WO2011148380A1 (en) * 2010-05-25 2011-12-01 Hetero Research Foundation Oral pharmaceutical composition of duloxetine

Also Published As

Publication number Publication date
MX2007011255A (en) 2007-10-18
IL184189A0 (en) 2007-10-31
IL184184A0 (en) 2007-10-31
WO2006099468A3 (en) 2007-04-05
WO2006099459A1 (en) 2006-09-21
MX2007011254A (en) 2007-10-18
EP1858874A1 (en) 2007-11-28
IL184185A0 (en) 2007-10-31
EP1858873A2 (en) 2007-11-28
US7534900B2 (en) 2009-05-19
WO2006099468A2 (en) 2006-09-21
EP1858859A1 (en) 2007-11-28
US20060276660A1 (en) 2006-12-07
WO2006099457A1 (en) 2006-09-21
TW200639162A (en) 2006-11-16
WO2006099433A1 (en) 2006-09-21
CA2599475A1 (en) 2006-09-21
US20060270861A1 (en) 2006-11-30
TW200639161A (en) 2006-11-16
CA2599478A1 (en) 2006-09-21
US20060258871A1 (en) 2006-11-16
EP1874754A1 (en) 2008-01-09

Similar Documents

Publication Publication Date Title
US20060270731A1 (en) Pure duloxetine hydrochloride
US7563930B2 (en) Crystal forms of Cinacalcet HCI and processes for their preparation
US7674935B2 (en) Crystal forms of O-desmethylvenlafaxine
US20070078158A1 (en) Purification of montelukast
US20070213404A1 (en) Processes for preparation of polymorphic form II of sertraline hydrochloride
WO2007120923A1 (en) Substantially pure o-desmethylvenlafaxine and processes for preparing it
US20080090835A1 (en) Polymorphic forms of ziprasidone HCl and processes for their preparation
US20110263719A1 (en) Polymorphic form of rasagiline mesylate
US7417165B2 (en) Crystalline forms of pregabalin
WO2007134168A2 (en) Process for preparing duloxetine
US7842717B2 (en) DNT-maleate and methods of preparation thereof
US20090012182A1 (en) Crystal forms of O-desmethylvenlafaxine succinate
US20070173541A1 (en) DNT-succinate and methods of preparation thereof
US20080027128A1 (en) Duloxetine HCL polymorphs
US20080207923A1 (en) Pure DNT-maleate and methods of preparation thereof
US20070191471A1 (en) DNT-fumarate and methods of preparation thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: TEVA PHARMACEUTICALS USA, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEVA PHARMACEUTICAL INDUSTRIES LTD;REEL/FRAME:018045/0752

Effective date: 20060719

Owner name: TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:INI, SANTIAGO;ABRAMOV, MILI;LIBERMAN, ANITA;REEL/FRAME:018044/0814;SIGNING DATES FROM 20060608 TO 20060621

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION